RecruitingPhase 1NCT06126406

Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors

Studying NON RARE IN EUROPE: Adenocarcinoma of stomach

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chongqing Precision Biotech Co., Ltd
Principal Investigator
lili Sheng, M.D
First Affiliated Hospital of Wannan Medical College
Intervention
CEA-targeted CAR-T cells(biological)
Enrollment
60 enrolled
Eligibility
18 years · All sexes
Timeline
20232026

Study locations (1)

Collaborators

First Affiliated Hospital of Wannan Medical College

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06126406 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Adenocarcinoma of stomach

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach

← Back to all trials